CalciMedica (CALC) EPS (Basic) Growth (3y) (2022 - 2026)
CalciMedica (CALC) EPS (Basic) Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | -38.31% |
| 10 | CalciMedica | 9.71 Mn | -8.91 Mn | - | 38.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.93% |
| Mar 31, 2026 | 74.81% |
| Dec 31, 2025 | 45.01% |
| Sep 30, 2025 | 36.21% |
| Jun 30, 2025 | 43.53% |
| Mar 31, 2025 | 44.02% |
| Dec 31, 2024 | 59.57% |
| Sep 30, 2024 | 54.21% |
| Jun 30, 2024 | 58.86% |
| Mar 31, 2024 | 26.03% |
| Dec 31, 2023 | 63.72% |
| Sep 30, 2023 | 71.53% |
| Jun 30, 2023 | 77.29% |
| Mar 31, 2023 | 36.74% |
| Dec 31, 2022 | 75.89% |
| Sep 30, 2022 | 74.24% |